Though the design of a biparatropic mAb which targets the epitopes for the existing therapeutic mAbs trastuzumab and pertuzumab, a combination already utilized in the treatment of late-stage breast cancer, has been discontinued due to toxicities, an alternative antibody targeting the trastuzumab epitope and a novel HER2 epitope is being evaluated [210]. Here, ERBB2 is linked to breast cancer.